

Rita Faria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8813311/publications.pdf>

Version: 2024-02-01

34
papers

1,597
citations

516710

16
h-index

454955

30
g-index

35
all docs

35
docs citations

35
times ranked

3897
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence for the impact of interventions and medicines reconciliation on problematic polypharmacy in the UK: A rapid review of systematic reviews. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 42-75.	2.4	7
2	Economic analysis of the prevalence and clinical and economic burden of medication error in England. <i>BMJ Quality and Safety</i> , 2021, 30, 96-105.	3.7	161
3	Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. <i>Applied Health Economics and Health Policy</i> , 2021, , 1.	2.1	10
4	Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2021, 338, 7-14.	0.8	4
5	Cost-effectiveness of strategies preventing late-onset infection in preterm infants. <i>Archives of Disease in Childhood</i> , 2020, 105, 452-457.	1.9	5
6	Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	2.8	8
7	Outcomes of reablement and their measurement: Findings from an evaluation of English reablement services. <i>Health and Social Care in the Community</i> , 2019, 27, 1438-1450.	1.6	20
8	Investigating the economic case of a service to support carers of people with dementia: A cross-sectional survey-based feasibility study in England. <i>Health and Social Care in the Community</i> , 2019, 27, e734-e743.	1.6	4
9	Specialist nursing support for unpaid carers of people with dementia: a mixed-methods feasibility study. <i>Health Services and Delivery Research</i> , 2019, 7, 1-198.	1.4	10
10	Reablement services for people at risk of needing social care: the MoRe mixed-methods evaluation. <i>Health Services and Delivery Research</i> , 2019, 7, 1-218.	1.4	22
11	Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? <i>Eur Urol</i> 2018;73:31-2. <i>European Urology</i> , 2018, 73, e151-e152.	1.9	0
12	Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial. <i>Pharmacoeconomics</i> , 2018, 36, 889-901.	3.3	69
13	Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). <i>European Urology</i> , 2018, 73, 23-30.	1.9	133
14	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018, 22, 1-176.	2.8	70
15	How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants. <i>Medical Decision Making</i> , 2017, 37, 148-161.	2.4	18
16	Quantifying Informal Care for Economic Evaluation in Mental Health. , 2017, , 267-280.		6
17	Models of reablement evaluation (MoRE): a study protocol of a quasi-experimental mixed methods evaluation of reablement services in England. <i>BMC Health Services Research</i> , 2016, 16, 375.	2.2	12
18	Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 981-992.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. Value in Health, 2016, 19, 138-144.	0.3	24
20	Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?. Pharmacoeconomics, 2016, 34, 427-433.	3.3	6
21	Economic Evaluation of Social Care Interventions: Lessons Drawn from a Systematic Review of the Methods Used to Evaluate Reablement. Health Economics & Outcome Research: Open Access, 2016, 02, .	0.1	1
22	A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT. Health Technology Assessment, 2015, 19, 1-188.	2.8	46
23	Optimizing the Position and Use of Omalizumab for Severe Persistent Allergic Asthma Using Cost-Effectiveness Analysis. Value in Health, 2014, 17, 772-782.	0.3	36
24	A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials. Pharmacoeconomics, 2014, 32, 1157-1170.	3.3	417
25	The economics of medicines optimization: policy developments, remaining challenges and research priorities. British Medical Bulletin, 2014, 111, 45-61.	6.9	10
26	Sleep apnoea in the elderly – Authors' reply. Lancet Respiratory Medicine, the, 2014, 2, e21-e22.	10.7	0
27	Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial. Lancet Respiratory Medicine, the, 2014, 2, 804-812.	10.7	175
28	The EOS 2D/3D X-ray imaging system: A cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure. European Journal of Radiology, 2013, 82, e342-e349.	2.6	49
29	Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. British Journal of Surgery, 2013, 100, 1205-1213.	0.3	41
30	A systematic review of the clinical effectiveness of EOS 2D/3D X-ray imaging system. European Spine Journal, 2013, 22, 296-304.	2.2	83
31	Dabigatran for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation: A NICE Single Technology Appraisal. Pharmacoeconomics, 2013, 31, 551-562.	3.3	15
32	Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX) Tj ETQq0 0 0 rgBT20verlock10 Tf 50 2		
33	Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technology Assessment, 2013, 17, 1-342.	2.8	75
34	Statistical analysis of clinical trial data for resource allocation decisions. , 0, , .		0